NanoBrand Competitors

As of February 27, 2026, Avidity Biosciences is now a Novartis Company. See full details on the completed acquisition here: https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy For further information and updates, please visit the Novartis US website (www.novartis.com/us-en/). Please note that select jobs will continue to be available on this channel.

NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret, and visualize complex and highly sensitive information, we enable customers in healthcare, life sciences, logistics, telecommunications and other industries to automate, understand and act on data while keeping it secure and scalable. Our product portfolio comprises the latest technology in payer-provider collaboration platforms for real-time coverage decision support, and data solutions that provide multi-data analysis, reporting and professional services offerings.

Horizon Discovery, formerly of PerkinElmer, and now part of the Revvity family, drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine. With more than a decade of experience in the engineering of cell lines, Horizon offers innovative tools and services based upon the ability to modulate, or permanently alter, the function of almost any gene in human and other mammalian cell lines. Horizon is headquartered in Cambridge, UK with offices in USA and Japan.